share_log

Capricor Therapeutics Completes Submission Of Biologics License Application To FDA for Deramiocel

Capricor Therapeutics Completes Submission Of Biologics License Application To FDA for Deramiocel

Capricor Therapeutics 完成了向FDA提交生物製品許可申請的工作,針對Deramiocel。
Benzinga ·  01/02 22:16

-If approved, deramiocel would be first approved therapy for Duchenne muscular dystrophy cardiomyopathy-

-如果獲得批准,deramiocel將成爲第一個被批准用於杜氏肌營養不良症心肌病的療法-

-BLA submission triggers $10 million milestone payment to Capricor from Nippon Shinyaku-

-BLA提交觸發了來自日本信藥的1000萬美元里程碑支付給Capricor-

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論